 David Kao
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 31 | 2023 | 1969 | 5.100 |
Why?
| | Stroke Volume | 16 | 2022 | 513 | 2.230 |
Why?
| | Machine Learning | 5 | 2022 | 331 | 1.930 |
Why?
| | Methadone | 5 | 2023 | 69 | 1.810 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 70 | 1.680 |
Why?
| | Adrenergic beta-Antagonists | 9 | 2019 | 301 | 1.660 |
Why?
| | Buprenorphine | 3 | 2023 | 136 | 1.590 |
Why?
| | Cardiomyopathies | 5 | 2022 | 299 | 1.570 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 277 | 1.280 |
Why?
| | Cardiomyopathy, Dilated | 8 | 2023 | 344 | 1.110 |
Why?
| | Electronic Health Records | 6 | 2022 | 829 | 1.080 |
Why?
| | Propanolamines | 3 | 2019 | 93 | 1.020 |
Why?
| | Torsades de Pointes | 4 | 2016 | 17 | 0.840 |
Why?
| | Telemedicine | 3 | 2020 | 664 | 0.800 |
Why?
| | Pulmonary Edema | 1 | 2021 | 125 | 0.800 |
Why?
| | Coffee | 1 | 2021 | 14 | 0.790 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 54 | 0.760 |
Why?
| | Stroke | 2 | 2021 | 1047 | 0.760 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 299 | 0.720 |
Why?
| | Mobile Applications | 1 | 2021 | 147 | 0.700 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 73 | 0.690 |
Why?
| | Humans | 77 | 2024 | 118974 | 0.690 |
Why?
| | Long QT Syndrome | 3 | 2016 | 57 | 0.690 |
Why?
| | Prosthesis Failure | 1 | 2020 | 120 | 0.680 |
Why?
| | Decision Support Systems, Clinical | 5 | 2023 | 178 | 0.680 |
Why?
| | Spironolactone | 1 | 2019 | 34 | 0.680 |
Why?
| | Device Removal | 1 | 2020 | 127 | 0.680 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 105 | 0.670 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 46 | 0.670 |
Why?
| | Medical Records | 2 | 2019 | 163 | 0.660 |
Why?
| | Coronary Disease | 1 | 2021 | 356 | 0.650 |
Why?
| | Artificial Intelligence | 1 | 2019 | 140 | 0.640 |
Why?
| | Mortality | 3 | 2019 | 299 | 0.640 |
Why?
| | Periodicals as Topic | 1 | 2020 | 191 | 0.640 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 46 | 0.610 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 794 | 0.610 |
Why?
| | United States | 19 | 2021 | 12555 | 0.600 |
Why?
| | Aged | 27 | 2022 | 19657 | 0.600 |
Why?
| | Atrial Fibrillation | 3 | 2019 | 338 | 0.590 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 53 | 0.580 |
Why?
| | Hospital Records | 1 | 2016 | 11 | 0.580 |
Why?
| | Risk Assessment | 7 | 2020 | 3057 | 0.570 |
Why?
| | Proteoglycans | 1 | 2017 | 109 | 0.570 |
Why?
| | Hospitalization | 9 | 2021 | 1785 | 0.550 |
Why?
| | Disease Management | 1 | 2020 | 571 | 0.540 |
Why?
| | Survival | 1 | 2015 | 39 | 0.530 |
Why?
| | Tetrazoles | 1 | 2015 | 32 | 0.530 |
Why?
| | Female | 43 | 2022 | 61565 | 0.530 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 52 | 0.520 |
Why?
| | Myocardial Infarction | 3 | 2018 | 968 | 0.510 |
Why?
| | Retrospective Studies | 19 | 2022 | 12978 | 0.500 |
Why?
| | Biomedical Research | 1 | 2020 | 612 | 0.490 |
Why?
| | Research Design | 1 | 2020 | 969 | 0.490 |
Why?
| | Registries | 2 | 2020 | 1810 | 0.480 |
Why?
| | Middle Aged | 25 | 2021 | 27617 | 0.480 |
Why?
| | Loperamide | 2 | 2023 | 10 | 0.470 |
Why?
| | United States Food and Drug Administration | 4 | 2016 | 175 | 0.470 |
Why?
| | Diet | 1 | 2021 | 1153 | 0.460 |
Why?
| | Precision Medicine | 6 | 2024 | 363 | 0.450 |
Why?
| | Myocardium | 3 | 2017 | 970 | 0.450 |
Why?
| | Male | 35 | 2022 | 57801 | 0.450 |
Why?
| | Muscle Proteins | 1 | 2015 | 219 | 0.450 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 151 | 0.450 |
Why?
| | Quality Improvement | 2 | 2020 | 963 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2062 | 0.440 |
Why?
| | Legislation, Medical | 1 | 2012 | 10 | 0.440 |
Why?
| | Peripartum Period | 4 | 2022 | 9 | 0.440 |
Why?
| | Amiodarone | 1 | 2012 | 24 | 0.430 |
Why?
| | Pharmacogenetics | 4 | 2021 | 151 | 0.430 |
Why?
| | Adult | 26 | 2022 | 31512 | 0.430 |
Why?
| | Patient Readmission | 1 | 2018 | 634 | 0.430 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 113 | 0.410 |
Why?
| | Catheter Ablation | 1 | 2015 | 286 | 0.410 |
Why?
| | Heart Arrest | 4 | 2019 | 291 | 0.400 |
Why?
| | Pyrazines | 2 | 2008 | 72 | 0.400 |
Why?
| | Postoperative Complications | 2 | 2020 | 2235 | 0.400 |
Why?
| | Hospital Mortality | 5 | 2022 | 814 | 0.390 |
Why?
| | Treatment Outcome | 9 | 2021 | 9342 | 0.380 |
Why?
| | Triazoles | 2 | 2008 | 134 | 0.380 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 485 | 0.380 |
Why?
| | Patient Transfer | 1 | 2012 | 143 | 0.370 |
Why?
| | Transfusion Reaction | 1 | 2011 | 79 | 0.370 |
Why?
| | Insurance, Health | 1 | 2012 | 244 | 0.370 |
Why?
| | Ventricular Function, Left | 4 | 2022 | 468 | 0.370 |
Why?
| | Patient Discharge | 2 | 2021 | 796 | 0.360 |
Why?
| | Databases, Factual | 5 | 2020 | 1231 | 0.360 |
Why?
| | Anemia | 1 | 2011 | 146 | 0.350 |
Why?
| | Thiazolidinediones | 1 | 2010 | 146 | 0.340 |
Why?
| | Marketing | 1 | 2008 | 25 | 0.340 |
Why?
| | Renal Insufficiency | 1 | 2011 | 150 | 0.330 |
Why?
| | Risk Factors | 8 | 2020 | 9000 | 0.330 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 18 | 0.330 |
Why?
| | Simvastatin | 1 | 2008 | 65 | 0.320 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 44 | 0.320 |
Why?
| | Heart Ventricles | 4 | 2017 | 727 | 0.320 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 53 | 0.320 |
Why?
| | Electrocardiography | 4 | 2019 | 556 | 0.310 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 25 | 0.310 |
Why?
| | Drug Industry | 1 | 2008 | 104 | 0.310 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1125 | 0.310 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 252 | 0.300 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 842 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1200 | 0.300 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2013 | 69 | 0.300 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 160 | 0.290 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 1865 | 0.290 |
Why?
| | Cardiovascular Diseases | 4 | 2021 | 1798 | 0.290 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 104 | 0.280 |
Why?
| | Young Adult | 9 | 2022 | 10793 | 0.260 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2445 | 0.260 |
Why?
| | Cause of Death | 2 | 2019 | 380 | 0.260 |
Why?
| | Ventricular Remodeling | 2 | 2017 | 229 | 0.260 |
Why?
| | Phenotype | 3 | 2020 | 3003 | 0.260 |
Why?
| | Pregnancy | 6 | 2022 | 5691 | 0.250 |
Why?
| | Glucose | 1 | 2010 | 953 | 0.250 |
Why?
| | Pandemics | 3 | 2022 | 1355 | 0.250 |
Why?
| | Incidence | 4 | 2021 | 2424 | 0.250 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 709 | 0.250 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 387 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1244 | 0.240 |
Why?
| | Adolescent | 10 | 2020 | 18480 | 0.240 |
Why?
| | Aged, 80 and over | 6 | 2020 | 6561 | 0.240 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.230 |
Why?
| | Sex Factors | 3 | 2019 | 1781 | 0.230 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 703 | 0.230 |
Why?
| | Prognosis | 5 | 2020 | 3443 | 0.220 |
Why?
| | Medicare | 2 | 2020 | 663 | 0.220 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 67 | 0.220 |
Why?
| | Naltrexone | 1 | 2023 | 80 | 0.220 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1032 | 0.210 |
Why?
| | Insulin Resistance | 1 | 2010 | 1180 | 0.200 |
Why?
| | Time Factors | 3 | 2020 | 6412 | 0.200 |
Why?
| | Smartphone | 1 | 2021 | 67 | 0.200 |
Why?
| | Referral and Consultation | 2 | 2017 | 648 | 0.200 |
Why?
| | Red Meat | 1 | 2021 | 13 | 0.200 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 34 | 0.200 |
Why?
| | Losartan | 1 | 2020 | 10 | 0.200 |
Why?
| | Actigraphy | 1 | 2021 | 80 | 0.200 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 21 | 0.190 |
Why?
| | Lisinopril | 1 | 2020 | 14 | 0.190 |
Why?
| | Speech | 1 | 2021 | 76 | 0.190 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 336 | 0.190 |
Why?
| | Hypertension | 2 | 2020 | 1203 | 0.190 |
Why?
| | Angioedema | 1 | 2020 | 17 | 0.190 |
Why?
| | Protective Factors | 1 | 2021 | 92 | 0.190 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 42 | 0.190 |
Why?
| | American Heart Association | 2 | 2019 | 270 | 0.190 |
Why?
| | Biological Products | 1 | 2023 | 170 | 0.190 |
Why?
| | Turner Syndrome | 1 | 2021 | 50 | 0.190 |
Why?
| | Data Accuracy | 1 | 2020 | 56 | 0.190 |
Why?
| | Software | 2 | 2015 | 613 | 0.190 |
Why?
| | Social Determinants of Health | 1 | 2022 | 129 | 0.190 |
Why?
| | California | 2 | 2012 | 382 | 0.180 |
Why?
| | Milk | 1 | 2021 | 125 | 0.180 |
Why?
| | Bionics | 1 | 2019 | 11 | 0.180 |
Why?
| | Editorial Policies | 1 | 2020 | 46 | 0.180 |
Why?
| | Medical Futility | 1 | 2019 | 22 | 0.180 |
Why?
| | Medical Informatics | 1 | 2020 | 102 | 0.180 |
Why?
| | Medical Record Linkage | 1 | 2020 | 53 | 0.180 |
Why?
| | Echocardiography | 2 | 2019 | 556 | 0.170 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 124 | 0.170 |
Why?
| | Drug Overdose | 1 | 2023 | 294 | 0.170 |
Why?
| | Prescription Drugs | 1 | 2020 | 113 | 0.170 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 30 | 0.170 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 42 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2021 | 248 | 0.170 |
Why?
| | Cohort Studies | 3 | 2021 | 5116 | 0.170 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 239 | 0.170 |
Why?
| | Tobacco Use | 1 | 2019 | 58 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 1945 | 0.160 |
Why?
| | Child Health Services | 1 | 2020 | 177 | 0.160 |
Why?
| | Genotype | 2 | 2021 | 1882 | 0.160 |
Why?
| | Computer Graphics | 2 | 2015 | 48 | 0.160 |
Why?
| | Cluster Analysis | 1 | 2019 | 481 | 0.160 |
Why?
| | Florida | 1 | 2018 | 73 | 0.160 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 10 | 0.160 |
Why?
| | Advisory Committees | 1 | 2019 | 212 | 0.160 |
Why?
| | Prospective Studies | 4 | 2021 | 6471 | 0.160 |
Why?
| | Length of Stay | 3 | 2021 | 1032 | 0.160 |
Why?
| | Forecasting | 1 | 2019 | 353 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4596 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2019 | 162 | 0.150 |
Why?
| | Cytochrome P-450 CYP2C19 | 3 | 2022 | 21 | 0.150 |
Why?
| | Academic Medical Centers | 1 | 2020 | 422 | 0.150 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 437 | 0.150 |
Why?
| | Nursing Assessment | 1 | 2017 | 46 | 0.150 |
Why?
| | Population Surveillance | 1 | 2020 | 413 | 0.150 |
Why?
| | Consensus | 1 | 2019 | 534 | 0.150 |
Why?
| | Patient Participation | 1 | 2020 | 369 | 0.150 |
Why?
| | Pressure Ulcer | 1 | 2017 | 33 | 0.150 |
Why?
| | Heart Diseases | 1 | 2020 | 341 | 0.140 |
Why?
| | Tilidine | 1 | 2016 | 1 | 0.140 |
Why?
| | Cardiology | 1 | 2019 | 272 | 0.140 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 104 | 0.140 |
Why?
| | Genetic Markers | 1 | 2017 | 348 | 0.140 |
Why?
| | Oxycodone | 1 | 2016 | 45 | 0.140 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 5 | 0.130 |
Why?
| | Rheumatic Fever | 1 | 2015 | 7 | 0.130 |
Why?
| | Sex Distribution | 1 | 2016 | 351 | 0.130 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 32 | 0.130 |
Why?
| | Computational Biology | 2 | 2017 | 588 | 0.130 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 17 | 0.130 |
Why?
| | Marijuana Use | 1 | 2018 | 157 | 0.130 |
Why?
| | Naloxone | 1 | 2016 | 98 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2017 | 253 | 0.130 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1597 | 0.130 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 23 | 0.130 |
Why?
| | Angiotensin II | 1 | 2015 | 107 | 0.130 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 42 | 0.130 |
Why?
| | United Kingdom | 1 | 2015 | 236 | 0.130 |
Why?
| | Mothers | 1 | 2020 | 682 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 770 | 0.120 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 455 | 0.120 |
Why?
| | Heart Rate | 2 | 2022 | 729 | 0.120 |
Why?
| | Age Factors | 2 | 2019 | 2995 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2015 | 122 | 0.120 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 136 | 0.120 |
Why?
| | Comorbidity | 1 | 2019 | 1527 | 0.120 |
Why?
| | Chronic Disease | 2 | 2020 | 1636 | 0.120 |
Why?
| | Cholesterol | 1 | 2015 | 373 | 0.110 |
Why?
| | Gene Expression | 2 | 2017 | 1489 | 0.110 |
Why?
| | MicroRNAs | 2 | 2017 | 637 | 0.110 |
Why?
| | Down-Regulation | 1 | 2015 | 627 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 374 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2017 | 2657 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 647 | 0.110 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 96 | 0.110 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 472 | 0.110 |
Why?
| | Federal Government | 1 | 2012 | 26 | 0.110 |
Why?
| | Drug Resistance | 1 | 2012 | 167 | 0.110 |
Why?
| | Area Under Curve | 1 | 2012 | 296 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1868 | 0.100 |
Why?
| | Colorado | 4 | 2024 | 4196 | 0.100 |
Why?
| | Patient Safety | 1 | 2015 | 281 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 109 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2275 | 0.100 |
Why?
| | Biomarkers | 1 | 2021 | 3588 | 0.100 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 349 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 208 | 0.100 |
Why?
| | Survival Rate | 1 | 2015 | 1720 | 0.100 |
Why?
| | Bayes Theorem | 1 | 2012 | 344 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 942 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2012 | 1687 | 0.090 |
Why?
| | Managed Care Programs | 2 | 2022 | 135 | 0.090 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 202 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1137 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1323 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2017 | 867 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2674 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1474 | 0.080 |
Why?
| | Primary Health Care | 1 | 2019 | 1560 | 0.080 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 35 | 0.080 |
Why?
| | Drug Approval | 1 | 2008 | 77 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2015 | 589 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2010 | 328 | 0.080 |
Why?
| | Logistic Models | 1 | 2012 | 1901 | 0.080 |
Why?
| | Animals | 3 | 2023 | 33381 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2007 | 164 | 0.070 |
Why?
| | Zimbabwe | 2 | 2017 | 39 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 417 | 0.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 245 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 965 | 0.070 |
Why?
| | Depression | 2 | 2022 | 1132 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2012 | 3171 | 0.070 |
Why?
| | Models, Biological | 1 | 2012 | 1715 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 4552 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 129 | 0.060 |
Why?
| | Mandible | 1 | 2004 | 65 | 0.060 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 38 | 0.060 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 36 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 736 | 0.060 |
Why?
| | Algorithms | 3 | 2020 | 1541 | 0.060 |
Why?
| | Child | 5 | 2020 | 19129 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 36 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 79 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 116 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 4 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 180 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 228 | 0.050 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 12 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2022 | 189 | 0.050 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 24 | 0.050 |
Why?
| | Health Services Misuse | 1 | 2020 | 36 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 446 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 296 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 460 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1974 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 31 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 37 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 194 | 0.040 |
Why?
| | Bias | 1 | 2020 | 198 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2459 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 706 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2025 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 233 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 311 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 388 | 0.040 |
Why?
| | Exercise Test | 1 | 2020 | 551 | 0.040 |
Why?
| | Focus Groups | 1 | 2019 | 387 | 0.040 |
Why?
| | Neoplasms | 1 | 2010 | 2179 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 105 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2016 | 13 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1129 | 0.040 |
Why?
| | Frail Elderly | 1 | 2017 | 107 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 176 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 333 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 490 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2016 | 33 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 107 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 291 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 83 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 113 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1664 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1079 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2874 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 985 | 0.030 |
Why?
| | Mass Screening | 2 | 2013 | 1052 | 0.030 |
Why?
| | Infant | 2 | 2015 | 8293 | 0.030 |
Why?
| | Models, Genetic | 1 | 2015 | 595 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 9491 | 0.020 |
Why?
| | Anthracyclines | 1 | 2010 | 41 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 92 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 84 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 4709 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 969 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 195 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 845 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 210 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2484 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 106 | 0.020 |
Why?
| | Mice | 1 | 2023 | 15520 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 380 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 716 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 667 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 491 | 0.020 |
Why?
| | Hospitals, University | 1 | 2005 | 172 | 0.020 |
Why?
| | Dentists | 1 | 2004 | 20 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1284 | 0.020 |
Why?
| | Femur Neck | 1 | 2004 | 65 | 0.010 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 60 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 229 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 142 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 21 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1293 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 449 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 583 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1224 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 951 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2071 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2871 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 794 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|